ndwarshuis
/
phd_thesis
1
0
Fork 0
Code Issues Pull Requests Packages Projects Releases Wiki Activity

ADD full survival curve to first mouse experiment

This commit is contained in:
Nathan Dwarshuis 2021-07-27 13:20:35 -04:00
parent c610ddb40e
commit e93859056d
2 changed files with 2004 additions and 1948 deletions
Show Stats Download Patch File Download Diff File Expand all files Collapse all files

3929
figures/mouse_dosing_ivis.svg
View File

File diff suppressed because one or more lines are too long
Side by Side Swipe Overlay

Before

Width:  |  Height:  |  Size: 3.2 MiB

After

Width:  |  Height:  |  Size: 3.3 MiB

23
tex/thesis.tex
View File

@ -1960,15 +1960,16 @@ of both the bead medium dose and the bead high dose
of Nalm-6 tumor bearing \gls{nsg} mice shown in the
\cref{fig:mouse_dosing_ivis_survival} was up to day 40 as reported
elsewhere\cite{Fraietta2018}. However, we also included a Kaplan-Meier figure up
to day 46 (Supplemental Figure 7) where most of the mice euthanized from day 40
through day 46 from \gls{dms} groups showed no or very small fragment of spleen
which was due to \gls{gvhd} responses. Similar \gls{gvhd} responses were
reported earlier in \gls{nsg} mice where the mice injected with human \gls{pbmc}
exhibited acute \gls{gvhd} between \SIrange{40}{50}{\day} post intravenous
injection\cite{Ali2012}. Notably, both survival analyses (up to day 40 in
\cref{fig:mouse_dosing_ivis_survival} and up to day 46 in Supplemental Figure 7)
confirmed that \gls{dms}-expanded groups outperformed bead-expanded groups in
terms of prolonging survival of Nalm-6 tumor challenged \gls{nsg} mice.
to day 46 (\cref{fig:mouse_dosing_ivis_survival_full}) where most of the mice
euthanized from day 40 through day 46 from \gls{dms} groups showed no or very
small fragment of spleen which was due to \gls{gvhd} responses. Similar
\gls{gvhd} responses were reported earlier in \gls{nsg} mice where the mice
injected with human \gls{pbmc} exhibited acute \gls{gvhd} between
\SIrange{40}{50}{\day} post intravenous injection\cite{Ali2012}. Notably, both
survival analyses (up to day 40 in \cref{fig:mouse_dosing_ivis_survival} and up
to day 46 in \cref{fig:mouse_dosing_ivis_survival_full}) confirmed that
\gls{dms}-expanded groups outperformed bead-expanded groups in terms of
prolonging survival of Nalm-6 tumor challenged \gls{nsg} mice.
Together, these data suggested that \glspl{dms} produce T cells that are not
only more potent that bead-expanded T cells (even when accounting for
@ -2026,6 +2027,7 @@ cells are effective at lower doses.
\phantomsubcaption\label{fig:mouse_dosing_ivis_plots}
\phantomsubcaption\label{fig:mouse_dosing_ivis_survival}
\phantomsubcaption\label{fig:mouse_dosing_ivis_survival_comp}
\phantomsubcaption\label{fig:mouse_dosing_ivis_survival_full}
\endgroup
\caption[Mouse Dosing IVIS and Survival Results]
@ -2038,6 +2040,9 @@ cells are effective at lower doses.
\subcap{fig:mouse_dosing_ivis_survival}{Survival plots of mice}
\subcap{fig:mouse_dosing_ivis_survival_comp}{Survival plots of mice showing
only those that received a comparable number of \gls{car} T cells.}
\subcap{fig:mouse_dosing_ivis_survival_full}{The same data as
\subref{fig:mouse_dosing_ivis_survival} except showing the full time until
euthanasia for all mice (including those that died via \gls{gvhd}).}
}
\label{fig:mouse_dosing_ivis}
\end{figure*}